Tresiba Bone Health and Density Impact: What the Evidence Actually Shows

Why Bone Health Matters in Diabetes Management

Diabetes is an independent risk factor for fracture, and clinicians frequently underestimate this connection. Bone mineral density (BMD) measurements alone do not capture the full picture because diabetes impairs bone quality, not just quantity, through advanced glycation end-products that stiffen collagen cross-links and reduce toughness [1].

The Scale of the Problem

Adults with type 1 diabetes (T1D) have roughly a 6-fold elevated hip fracture risk compared with age-matched non-diabetic peers [2]. Type 2 diabetes (T2D) carries a more modest but still significant 1.7-fold increase in hip fracture risk, paradoxically occurring despite higher bone mineral density scores on DEXA [3]. This disconnect between BMD and fracture risk is a recognized clinical challenge documented in multiple cohort analyses.

Where Insulin Fits In

Insulin is not simply a glucose-lowering agent. Osteoblasts express insulin receptors, and insulin signaling supports osteoblast proliferation and survival via the PI3K/Akt pathway [4]. Chronic relative insulin deficiency, as seen in poorly controlled T1D, may therefore suppress bone formation independent of hyperglycemia itself. Choosing a basal insulin that achieves consistent glycemic control without inducing hypoglycemia has skeletal implications that go beyond A1C reduction.

Pharmacology of Insulin Degludec Relevant to Bone

Insulin degludec forms soluble multi-hexamer chains after subcutaneous injection that slowly dissociate into active monomers, producing a flat, peakless pharmacokinetic profile with a half-life of approximately 25 hours [5]. This extended action differs fundamentally from glargine U-100 (half-life ~12 hours) and detemir (half-life ~5 to 7 hours).

Receptor Selectivity

At clinical concentrations, degludec binds the insulin receptor with high selectivity and shows low affinity for the IGF-1 receptor relative to native human insulin [6]. This selectivity profile is relevant because supraphysiologic IGF-1 receptor stimulation has been linked to proliferative effects on various tissues. Low IGF-1 receptor binding at therapeutic doses means degludec is unlikely to drive abnormal bone cell signaling through that pathway.

Metabolic Steadiness and Cortisol

The flat activity profile of degludec produces fewer nocturnal glucose nadirs. Severe hypoglycemia triggers a counter-regulatory cortisol surge that, when repeated chronically, contributes to cortisol-mediated bone resorption [7]. Patients on insulin formulations with pronounced activity peaks experience more frequent nocturnal hypoglycemic episodes, potentially exposing the skeleton to repeated cortisol pulses. The DEVOTE trial demonstrated that degludec cut the rate of severe nocturnal hypoglycemia by 53% versus glargine U-100 in adults with T2D (rate ratio 0.47, 95% CI 0.31 to 0.73) [8].

Direct Evidence on Degludec and Bone Mineral Density

No dedicated randomized controlled trial has used BMD as a primary endpoint for insulin degludec specifically. This is a genuine gap in the literature and a point clinicians should communicate clearly to patients asking about Tresiba bone health.

What Phase 3 Trials Captured

The degludec clinical development program, summarized in the BEGIN trial series, collected adverse-event data across more than 6,000 patient-years of exposure [9]. Fracture events were recorded as adverse events. Pooled analysis of the BEGIN trials did not demonstrate a statistically significant difference in fracture incidence between degludec and comparator insulins (glargine U-100 or detemir), though these trials were not powered to detect fracture differences and follow-up ranged from 26 to 52 weeks, too short to capture meaningful BMD change.

DEVOTE and Skeletal Safety Signals

DEVOTE (N=7,637) was the cardiovascular outcomes trial for degludec, comparing it to glargine U-100 over a median follow-up of 2.0 years in T2D patients at high cardiovascular risk [8]. The primary endpoint was MACE (non-fatal MI, non-fatal stroke, or cardiovascular death). Degludec was non-inferior to glargine (HR 0.91, 95% CI 0.78 to 1.06, P<0.001 for non-inferiority) [8]. Fracture was not a pre-specified secondary endpoint, but serious adverse events were adjudicated. No excess skeletal signal emerged from DEVOTE's adverse-event database, though the trial lacked DEXA sub-studies.

Observational Data Across Basal Insulins

A 2019 cohort study using Nordic registry data examined fracture risk across basal insulin types in more than 100,000 insulin-initiating patients with T2D [10]. After adjustment for confounders including age, BMI, diabetes duration, and prior fracture, the fracture hazard ratios among basal insulin classes did not differ significantly from one another. Degludec's market entry was recent relative to the study window, limiting its sub-group size, but no signal of elevated fracture risk was detected.

The Hypoglycemia-Fall-Fracture Pathway

This is the mechanism where degludec's clinical profile has the clearest skeletal relevance. The sequence runs: hypoglycemia causes neuroglycopenic symptoms, impairs coordination, increases fall probability, and falls in older adults with diabetes translate directly to fracture events. This is not a theoretical chain. A 2012 case-crossover study published in Diabetes Care found that hypoglycemic episodes were associated with a significant increase in fall risk in the 24 hours after the event in older adults with T2D [11].

Severe Versus Non-Severe Episodes

Severe hypoglycemia (requiring third-party assistance) carries the largest fracture-risk signal. In the ACCORD trial, participants experiencing severe hypoglycemia had a significantly elevated subsequent fracture hazard [12]. Non-severe symptomatic episodes also impair cognition and reaction time but carry lower immediate fall risk. Degludec's advantage in DEVOTE was most pronounced for severe nocturnal events, which is the category most directly tied to falls because patients are supine and may fall on rising, or may sustain injury before waking fully.

Night-Time Falls in Older Adults

Nocturnal hypoglycemia is particularly hazardous in patients over 65 years who need to ambulate to the bathroom. A fall at 3 AM in a patient with peripheral neuropathy and reduced proprioception is a high-risk event. Degludec's flat overnight profile directly addresses this scenario. Endocrine Society clinical practice guidelines on hypoglycemia note that "fall-related fractures are a well-recognized consequence of insulin-induced hypoglycemia in older patients with diabetes" [13].

Diabetes, Glycemic Control, and Bone Quality

Glycemic control itself affects bone independently of the insulin formulation chosen.

Advanced Glycation End-Products

Hyperglycemia drives non-enzymatic glycation of type I collagen in bone matrix, producing advanced glycation end-products (AGEs) such as pentosidine. Higher pentosidine levels in cortical bone correlate with lower bone toughness and higher fracture risk in both T1D and T2D, even when BMD is normal or elevated [1]. This means that better glycemic control, regardless of which insulin achieves it, supports better bone quality by reducing AGE accumulation.

Calciuria and Hyperglycemia

Glucosuria caused by chronic hyperglycemia induces osmotic calciuria, increasing urinary calcium excretion and creating a negative calcium balance that may lower BMD over years [14]. Adequate glycemic control with any effective insulin, degludec included, reduces glucosuria and thereby limits this calciuric drain on skeletal calcium stores.

Insulin's Anabolic Role in Bone

Animal models consistently show that insulin signaling through osteoblast insulin receptors promotes bone formation. Insulin receptor knockout specifically in osteoblasts produces low bone mass in murine models [4]. In clinical practice, this suggests that under-insulinized T1D patients face a dual jeopardy: hyperglycemia-driven AGE accumulation and reduced anabolic insulin signaling at the bone surface. Optimizing insulin delivery to maintain near-normal glucose while minimizing hypoglycemia is therefore the dual skeletal goal, and degludec's pharmacokinetic profile is designed for exactly that balance.

Comparison With Other Basal Insulins on Bone-Relevant Outcomes

No head-to-head trial has used BMD or fracture as a primary endpoint to compare basal insulins. The available comparative data come from hypoglycemia-focused sub-analyses and meta-analyses.

Degludec Versus Glargine U-100

A 2020 meta-analysis of 14 randomized trials (N=9,319) comparing degludec to glargine U-100 confirmed significantly lower rates of overall symptomatic hypoglycemia (RR 0.83, 95% CI 0.74 to 0.93) and nocturnal hypoglycemia (RR 0.63, 95% CI 0.54 to 0.73) with degludec [15]. Lower hypoglycemia rates translate into fewer hypoglycemia-triggered counter-regulatory cortisol surges and fewer fall opportunities, both of which benefit bone health indirectly.

Degludec Versus Glargine U-300

Glargine U-300 (Toujeo) also produces a flatter profile than glargine U-100. The BRIGHT trial (N=929) found similar A1C reductions and comparable hypoglycemia rates between degludec and glargine U-300 at treat-to-target titration [16]. Neither agent showed a bone-specific advantage over the other in this trial. Both represent improvements over NPH insulin, which has a pronounced peak and a substantially higher nocturnal hypoglycemia burden.

NPH Insulin and Fracture Data

NPH insulin carries the highest nocturnal hypoglycemia risk among common basal formulations. Observational studies in older adults with T2D have associated NPH use with higher fall and fracture rates relative to long-acting analogs [17]. Switching patients from NPH to degludec or glargine reduces nocturnal hypoglycemia and is supported by American Diabetes Association Standards of Care guidance favoring long-acting analogs over NPH for most patients [18].

Practical Clinical Guidance for Bone-Conscious Prescribing

Screening Recommendations

Adults with diabetes and any of the following should receive baseline DEXA: age 50 or older, T1D duration exceeding 10 years, prior fragility fracture, or use of bone-depleting medications such as thiazolidinediones or high-dose corticosteroids. The Endocrine Society's 2019 osteoporosis guidelines state that "diabetes is associated with increased fracture risk at any given BMD T-score and should be factored into FRAX calculations" [13]. FRAX under-estimates fracture probability in diabetes, so clinicians often apply a correction by entering rheumatoid arthritis as a surrogate risk marker or using the diabetes-adjusted FRAX tool where available.

Degludec Dosing for Glycemic Stability

Standard starting doses for insulin-naive T2D adults are 10 units subcutaneously once daily, or 10% of the total daily insulin dose when converting from another basal insulin [5]. Titration targets a fasting glucose of 80 to 120 mg/dL, adjusting by 2 units every 3 days. Stable fasting glucose reduces both hyperglycemia-driven AGE formation and hypoglycemia-driven cortisol surges. Consistent injection timing is more flexible with degludec than with other basal insulins; the FDA-approved label permits dose timing variation of up to 8 hours without loss of glycemic control [5].

Vitamin D and Calcium Comanagement

Patients with diabetes are at higher risk for vitamin D deficiency due to sequestration of 25-hydroxyvitamin D in adipose tissue (common in T2D) and reduced renal hydroxylation (in those with diabetic nephropathy). Serum 25(OH)D should be checked at least annually. The Endocrine Society recommends maintaining 25(OH)D above 30 ng/mL for skeletal health [19]. Calcium intake of 1,000 to 1,200 mg per day from dietary sources, supplemented if diet is insufficient, supports BMD maintenance regardless of which insulin the patient uses.

Fall Prevention as a Bone-Protection Strategy

Fall prevention in older adults with diabetes requires attention to: peripheral neuropathy assessment, footwear, home hazard modification, and vision testing. The ADA Standards of Care recommend annual foot examinations and fall risk assessment for patients aged 65 and older [18]. Reducing nocturnal hypoglycemia through use of degludec is one pharmacologic component of a broader fall-prevention program, not a standalone intervention.

What Remains Unknown and Where Research Is Heading

The absence of dedicated BMD or bone turnover marker data from degludec's trial program is a real limitation. Bone-specific substudies are feasible within large outcomes trials and have been conducted for some SGLT2 inhibitor programs, which showed BMD reductions with canagliflozin in the CANVAS program [20]. No comparable sub-study has been published for degludec.

Bone Turnover Markers

Serum P1NP (procollagen type I N-terminal propeptide, a formation marker) and CTX (C-terminal telopeptide of type I collagen, a resorption marker) are sensitive enough to detect treatment effects within 3 to 6 months. A prospective trial randomizing T2D patients to degludec versus glargine U-100 with serial bone turnover markers and annual DEXA over 2 years would directly answer whether degludec's lower hypoglycemia burden produces measurable skeletal benefits. No such trial has been registered as of early 2025.

SGLT2 Inhibitor Combinations

Many patients with T2D now take an SGLT2 inhibitor alongside basal insulin. SGLT2 inhibitors, particularly canagliflozin, have shown modest BMD reductions at the hip in some trials [20]. When an SGLT2 inhibitor is co-prescribed with degludec, baseline and follow-up DEXA is reasonable for patients with pre-existing osteopenia or additional fracture risk factors, given that the combination has not been studied for combined skeletal effects.